AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20196118
Drug: 16 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 16 weeks of peginterferon alfa‐2a (40KD) 180 microg/week plus ribavirin 800 mg/day
Trial: 20196118
Drug: 24 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 24 weeks of treatment in genotype 2
Trial: 20196118
Drug: 16 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 16 weeks of treatment in genotype 2
Trial: 20196118
Drug: 24 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 24 weeks of treatment in genotype 3
Trial: 20196118
Drug: 16 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 16 weeks of treatment in genotype 3
Trial: 18613251
Drug: Novel combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel combination of models estimating hazard rate
Trial: 14520130
Drug: Nefazodone and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefazodone and Fluoxetine
Trial: 10919932
Drug: n‐3 fatty
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n‐3 fatty acid‐enriched oil (supplement)
Trial: 1364197
Drug: 0.1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg/kg midazolam (n = 7)
Trial: 1364197
Drug: 0.05 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 mg/kg vecuronium (n = 8)
Trial: 12974184
Drug: saccharosum +
RxNorm normalized name: Acer saccharinum pollen
DrugBank: Acer saccharinum pollen (DB10735)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saccharosum + sennosid-B solution
Trial: 28965122
Drug: Hyperbaric bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric bupivacaine (7.20 mg ED50 for motor block)
Trial: 28965122
Drug: Plain bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plain bupivacaine (10.05 mg ED50 for motor block)
Trial: 23208128
Drug: EGFR tyrosine
RxNorm normalized name: Tyrosine
DrugBank: Tyrosine (DB00135)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EGFR tyrosine kinase inhibitors (TKI)
Trial: 23208128
Drug: Chemotherapy among
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy among the three groups
Trial: 10224735
Drug: 18 sessions
RxNorm normalized name: Alpinia Sessilis Root
DrugBank: Kaempferia galanga root (DB14288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18 sessions of twice-weekly exposure therapy
Trial: 10224735
Drug: 18 sessions
RxNorm normalized name: Alpinia Sessilis Root
DrugBank: Kaempferia galanga root (DB14288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18 sessions of twice-weekly exposure therapy followed by 16 sessions of behavioral family therapy (BFT)
Trial: 8630312
Drug: All oral
RxNorm normalized name: Exall Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All oral contraceptives studied
Trial: 6356972
Drug: Epidural fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Epidural fentanyl concentrations below 10 micrograms/ml
Trial: 6356972
Drug: More dilute
RxNorm normalized name: polyurethane-35 (not more than MPA.S at 40 %)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: More dilute solutions of epidural fentanyl
Trial: 27930447
Drug: Carbohydrate and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate and caffeine (CHO-C) (40 g·h + 3 mg·kg)
Trial: 27930447
Drug: Carbohydrate (CHO;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate (CHO; 40 g·h)
Trial: 24738883
Drug: Preservative-free fixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preservative-free fixed combination (FC) of tafluprost 0.0015%/timolol 0.5%
Trial: 24738883
Drug: Non-fixed combination
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-fixed combination (NFC) of tafluprost 0.0015% and timolol 0.5%
Trial: 1960551
Drug: IFN‐alpha 2A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN‐alpha 2A 20 x 10(6) U/m2 intramuscularly three times a week with ASA 600 mg orally four times daily
Trial: 7014349
Drug: Insulin and
RxNorm normalized name: Isophane insulin and porcine regular insulin only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin and glucagon infusion (24 U regular insulin and 2.4 mg glucagon over 12 h daily for 3 weeks)
Trial: 7014349
Drug: Dextrose solution
RxNorm normalized name: Dextrose solution
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextrose solution (200 ml over the same time period)
Trial: 31500494
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment at 20 mmHg
Trial: 28576350
Drug: Sativex Oromucosal
RxNorm normalized name: Castanea sative leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sativex Oromucosal Spray (active group, n=15)
Trial: 25538173
Drug: Bevacizumab plus
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab plus FOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 165 mg/m2, folinic acid 200 mg/m2, 5-fluorouracil 3200 mg/m2 every 2 weeks)
Trial: 25538173
Drug: Bevacizumab plus
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab plus mFOLFOX-6 (oxaliplatin 85 mg/m2, folinic acid 400 mg/m2, 5-fluorouracil 400 mg/m2 bolus then 2400 mg/m2 46-h infusion every 2 weeks)
Trial: 23667876
Drug: Neuroprotector Cortexin
RxNorm normalized name: adrenal cortex extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuroprotector Cortexin added to standard drug therapy
Trial: 17505806
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (tizanidine, fluoxetine, vinpocetin, and manual acupressure)
Trial: 12772723
Drug: New hyper-oxygen
RxNorm normalized name: Hyper-Sal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New hyper-oxygen transmissible lenses (daily and extended wear)
Trial: 10761262
Drug: Maximal androgen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maximal androgen deprivation prior to and during definitive radiation therapy
Trial: 1383434
Drug: 20 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 Gy RT (radiation therapy) after good response to chemotherapy
Trial: 3315765
Drug: Intranasal human
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal human insulin 100 U/ml with sodium glycocholate 4 % w/v, administered as a spray solution (0.5 U/Kg b.w.)
Trial: 3315765
Drug: Intranasal regular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal regular porcine and human insulin 40 U/ml with sodium glycocholate 1 % w/v, administered in drops (0.9 U/Kg b.w.)
Trial: 20353621
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Group Therapy (CBGT) with Motivational Interviewing (MI) and Thought Mapping (TM)
Trial: 10868622
Drug: Antiviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiviral therapy in CMV seronegative recipients
Trial: 1442491
Drug: amiodarone plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: amiodarone plus xamoterol (200 mg two times daily)
Trial: 1442491
Drug: amiodarone plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: amiodarone plus metoprolol (50 mg two times daily)
Trial: 1442491
Drug: amiodarone plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: amiodarone plus beta-blockers (metoprolol or xamoterol)
Trial: 2857633
Drug: 5-aminosalicylic acid
RxNorm normalized name: 5-aminosalicylic acid
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-aminosalicylic acid (0.5 g t.i.d.)
Trial: 2857633
Drug: salazosulfapyridine (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: salazosulfapyridine (1.0 g t.i.d.)
Trial: 18640933
Drug: mFOLFOX6 (bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mFOLFOX6 (bolus and infusion fluorouracil [FU] and leucovorin [LV] with oxaliplatin)
Trial: 18640933
Drug: bFOL (bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bFOL (bolus FU and low-dose LV with oxaliplatin)
Trial: 16447879
Drug: Large dosage
RxNorm normalized name: Bos taurus large intestine preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Large dosage of salvia injection (24 ml)
Trial: 16447879
Drug: Middle dosage
RxNorm normalized name: wheat middlings extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Middle dosage of salvia injection (16 ml)
Trial: 16447879
Drug: Small dosage
RxNorm normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small dosage of salvia injection (8 ml)
Trial: 16447879
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no salvia injection)
Trial: 16447879
Drug: Overall efficacy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall efficacy of salvia injection
Trial: 19667506
Drug: Sulfonylureas, repaglinide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfonylureas, repaglinide, metformin, acarbose, thiazolidinediones
Trial: 8979780
Drug: OAM (omeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OAM (omeprazole 20 mg daily, amoxycillin 500 mg tid, metronidazole 400 mg tid)
Trial: 8979780
Drug: RAM (ranitidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAM (ranitidine 600 mg bd, amoxycillin 500 mg tid, metronidazole 400 mg tid)
Trial: 8979780
Drug: OC (omeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OC (omeprazole 20 mg daily, clarithromycin 500 mg tid)
Trial: 8979780
Drug: OP (omeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OP (omeprazole 20 mg daily and placebo)
Trial: 1279170
Drug: Intravenous iloprost
RxNorm normalized name: Iloprost
DrugBank: Iloprost (DB01088)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous iloprost (0.5-2.0 ng/kg/min)
Trial: 27243567
Drug: Group Cognitive
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group Cognitive Processing Therapy‐Cognitive Only Version
Trial: 27243567
Drug: Group Present‐Centered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group Present‐Centered Therapy
Trial: 27243567
Drug: Participants who
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants who no longer met criteria for PTSD following treatment
Trial: 24684977
Drug: Sleep medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sleep medication use
Trial: 15705230
Drug: Lyc‐o‐Mato((R)) drink
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lyc‐o‐Mato((R)) drink (250 ml daily providing about 6 mg lycopene, 4 mg phytoene, 3 mg phytofluene, 1 mg beta‐carotene, and 1.8 mg alpha‐tocopherol)
Trial: 10369848
Drug: Sotalol (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sotalol (160 to 320 mg per day)
Trial: 7725845
Drug: Calcitonin (CT)
DrugBank: Calcitonin porcine (DB13189)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcitonin (CT) treatment with 100 IU and 250 mg calcium 3 times a week
Trial: 7725845
Drug: Routine thalassemia
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine thalassemia therapy (Control)
Trial: 2202804
Drug: Diazepam (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (0.5 mg/kg, then 0.20 mg/kg, every 12 hours)
Trial: 7032343
Drug: Budesonide nasal
RxNorm normalized name: budesonide nasal
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide nasal spray 200 micrograms b.i.d.
Trial: 30326770
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin (iOT)
Trial: 24819432
Drug: Multimodal physiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multimodal physiotherapy program (MPP) twice a week (G2: n=58)
Trial: 23969334
Drug: Hinokitiol-containing gel
RxNorm normalized name: sodium hinokitiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hinokitiol-containing gel
Trial: 23969334
Drug: Control gel
RxNorm normalized name: SALICYLIC ACID 20 mg in 1 mL TOPICAL GEL [Walgreens Acne Control Gel]
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control gel (not containing hinokitiol)
Trial: 19273704
Drug: Doxorubicin 75
RxNorm normalized name: DOXOrubicin 75 mg intravenous powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin 75 mg/m² every 3 weeks for 6 cycles (arm A)
Trial: 19273704
Drug: Doxorubicin 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin 30 mg/m² per day for 3 consecutive days every 2 weeks for 3 cycles followed by ifosfamide 12.5 g/m² over 5 days every 3 weeks for 3 cycles (arm B)
Trial: 19273704
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard-dose doxorubicin)
Trial: 11552108
Drug: Warmed intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warmed intravenous fluids (IVF)
Trial: 11552108
Drug: Nonwarmed intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonwarmed intravenous fluids
Trial: 7867872
Drug: Twice-weekly thyroxine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-weekly thyroxine therapy
Trial: 7867872
Drug: Daily thyroxine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily thyroxine therapy
Trial: 334212
Drug: Fenfluramine, 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenfluramine, 120 mg daily
Trial: 19375948
Drug: Partial-breast irradiation
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Partial-breast irradiation (intraoperative radiation therapy)
Trial: 19375948
Drug: Whole-breast radiation
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-breast radiation therapy
Trial: 14693787
Drug: External beam
RxNorm normalized name: Beam
DrugBank: Tricyclazole (DB02891)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: External beam irradiation with five fractions of 3 Gy (total dose 15 Gy)
Trial: 14693787
Drug: External beam
RxNorm normalized name: Beam
DrugBank: Tricyclazole (DB02891)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: External beam irradiation with seven fractions of 2 Gy (total dose 14 Gy)
Trial: 11452166
Drug: Epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epoetin alfa (600 IU/kg) plus oral iron (n = 29)
Trial: 11452166
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus oral iron (n = 27)
Trial: 9635707
Drug: Pelvic radiotherapy
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pelvic radiotherapy and bolus 5-fluorouracil-based chemotherapy
Trial: 7977118
Drug: Intravenous diltiazem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous diltiazem (0.25 mg/kg over 2 minutes, followed by 0.35 mg/kg if needed)
Trial: 7977118
Drug: Open-label intravenous
RxNorm normalized name: Ga-68-Labeled PSMA-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label intravenous diltiazem after placebo
Trial: 2698566
Drug: Diltiazem 90
RxNorm normalized name: diltiazem 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem 90 mg
Trial: 30940760
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (WHO recommended first-line treatment)
Trial: 26882608
Drug: Jinying Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jinying Capsule (JC), 0.5 g per capsule, 4 capsules each time, 3 times per day for 4 weeks
Trial: 26882608
Drug: Kangfuyan Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kangfuyan Capsule (KC), 0.4 g per capsule, 3 capsules each time, twice per day for 4 weeks
Trial: 26882608
Drug: Jinying Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jinying Capsule (JC)
Trial: 26882608
Drug: Kangfuyan Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kangfuyan Capsule (KC)
Trial: 21221982
Drug: Clomiphene citrate/gonadotropin/antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate/gonadotropin/antagonist (mild protocol)
Trial: 21221982
Drug: Microdose GnRH
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Microdose GnRH agonist flare (group II)
Trial: 12635578
Drug: Topical nasal
RxNorm normalized name: Nasal Inhalant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical nasal fluticasone (50 micrograms per spray, 2 sprays each side every day)
Trial: 12635578
Drug: Topical nasal
RxNorm normalized name: Nasal Inhalant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical nasal fluticasone
Trial: 8311273
Drug: General Anesthesia
RxNorm normalized name: Ethers for general anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General Anesthesia (GA) with high dose of opioid anesthetic, n = 12
Trial: 26317629
Drug: Preoperative Oral
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative Oral Carbohydrate (CHO)
Trial: 26317629
Drug: Preoperative Oral
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative Oral Rehydration Solution (ORS)
Trial: 18077730
Drug: Raltegravir 400
RxNorm normalized name: raltegravir 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltegravir 400 mg every 12 hours for 14 days
Trial: 18077730
Drug: Midazolam 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 2.0 mg
Trial: 12589525
Drug: Caffeinated drink
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeinated drink (100 mg caffeine)
Trial: 10880013
Drug: Adenoviral vector
RxNorm normalized name: Adenoviral vector-RheoSwitch Therapeutic System-human interleukin 12
DrugBank: Ad-RTS-hIL-12 (DB17177)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenoviral vector delivered intraperitoneally (i.p.) at varying doses (2 x 10(10) to 2 x 10(13) vector particles) with concomitant topotecan chemotherapy and acyclovir.
Trial: 27003457
Drug: Amino acid
RxNorm normalized name: Amino Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid administration
Trial: 8252937
Drug: Amrinone (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amrinone (1.5 mg/kg loading dose plus 10 micrograms/kg/min maintenance infusion; n = 20)
Trial: 3828182
Drug: Extradural infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extradural infusion of 0.125% bupivacaine (Marcain) 10 ml (12.5 mg) per hour during labour
Trial: 3828182
Drug: Extradural infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extradural infusion of 0.125% bupivacaine (Marcain)
Trial: 26538631
Drug: Urine L-FABP
RxNorm normalized name: Urin DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urine L-FABP
Trial: 18199022
Drug: diclofenac sodium,
RxNorm normalized name: diclofenac sodium, micronized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diclofenac sodium, 50 mg (taken orally, 3 times per day)
Trial: 15728371
Drug: Three doses
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses of transgenic potatoes (100 g of tuber, HBsAg at approximately 8.5 microg/g)
Trial: 15728371
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of transgenic potatoes (100 g of tuber, HBsAg at approximately 8.5 microg/g)
Trial: 12947369
Drug: Pyridostigmine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyridostigmine (30 mg orally 3 times daily for 2 days)
Trial: 6649975
Drug: Intravenous Metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous Metronidazole
Trial: 6649975
Drug: Intravenous Metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous Metronidazole combined with intravenous Gentamycin
Trial: 31321427
Drug: Medication cost
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication cost transparency alerts for high-cost medications
Trial: 28139972
Drug: AR-C124910XX 60
RxNorm normalized name: AR-9281
DrugBank: AR-9281 (DB06345)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AR-C124910XX 60 mg twice daily
Trial: 28139972
Drug: AR-C124910XX 90
RxNorm normalized name: AR-9281
DrugBank: AR-9281 (DB06345)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AR-C124910XX 90 mg twice daily
Trial: 22848766
Drug: 40 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/kg praziquantel (PZQ)
Trial: 22848766
Drug: 75 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg/kg praziquantel (PZQ)
Trial: 20673554
Drug: Adjunctive armodafinil
RxNorm normalized name: Armodafinil
DrugBank: Armodafinil (DB06413)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjunctive armodafinil 150 mg/d
Trial: 16337461
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate nasal spray 200 microg twice daily